603965-77-1

Basic information

• Product Name: Ethyl 2-(piperazin-1-yl)pyrimidine-5-carboxylate
• Synonyms: Ethyl 2-(piperazin-1-yl)pyrimidine-5-carboxylate;Ethyl 2-piperazin-1-ylpyriMidin-5-carboxylate;5-PyriMidinecarboxylic acid, 2-(1-piperazinyl)-, ethyl ester
• CAS NO: 603965-77-1
• Molecular Formula: C₁₁H₁₆N₄O₂
• Molecular Weight: 236.27
• Product Categories: pharmacetical
• Mol File: 603965-77-1.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 407.2°C at 760 mmHg
• Flash Point: 200.1°C
• Appearance: /
• Density: 1.189g/cm³
• Vapor Pressure: 7.69E-07mmHg at 25°C
• Refractive Index: 1.54
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethyl 2-(piperazin-1-yl)pyrimidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-(piperazin-1-yl)pyrimidine-5-carboxylate(603965-77-1)
• EPA Substance Registry System: Ethyl 2-(piperazin-1-yl)pyrimidine-5-carboxylate(603965-77-1)

Safety Data

• Hazardous Substances Data: 603965-77-1(Hazardous Substances Data)

Usage

General Description

Ethyl 2-(piperazin-1-yl)pyrimidine-5-carboxylate is a chemical compound with the molecular formula C13H18N4O2. It is a pyrimidine derivative with a piperazine group attached to the 2-position and an ethyl ester group attached to the 5-position of the pyrimidine ring. Ethyl 2-(piperazin-1-yl)pyrimidine-5-carboxylate has been studied for its potential pharmaceutical applications, including as a building block for the synthesis of various drugs and other bioactive compounds. It may also have potential biological activities such as antiviral or antimicrobial properties. Additionally, it is important to handle this chemical with care, as it may have potential health hazards if not properly managed.

InChI:InChI=1/C11H16N4O2/c1-2-17-10(16)9-7-13-11(14-8-9)15-5-3-12-4-6-15/h7-8,12H,2-6H2,1H3

Upstream product

• 110-85-0 piperazine 
• 89793-12-4 ethyl 2-chloropyrimidine-5-carboxylate 
• 33458-27-4 ethyl 2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
• 763-69-9 ethyl 3-ethoxypropionate 
• 95928-49-7 ethyl 2-oxo-1,2-dihydropyrimidine-5-carboxylate 
• 879008-23-8 (Z)-ethyl-2-(ethoxymethyl)-3-methoxyacrylate 
• 253315-69-4 ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylate 
• 148550-51-0 ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate 
• 2974-30-3 (Z)-ethyl-2-(ethoxymethyl)-3-methoxyacrylate 
• 374930-88-8 tert-butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate 
• 64-17-5 ethanol 
• 253315-11-6 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylic acid 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 842170-25-6 C₂₂H₂₆F₃N₅O₂ 
• 603991-95-3 C₂₃H₂₃N₅O₃ 
• 1417790-19-2 ethyl 2-(4-(2-(trifluoromethyl)benzoyl)piperazin-1-yl)-pyrimidine-5-carboxylate 
• 935670-64-7 C₂₇H₂₅N₅O₄ 
• 875138-60-6 C₂₁H₂₆N₄O₂ 
• 875138-55-9 C₂₁H₂₅ClN₄O₃ 
• 875138-52-6 C₂₁H₂₆N₄O₃ 

Relevant articles and documents

Compound for inducing BCR-ABL protein degradation through targeted ubiquitination and application thereof

The invention provides a compound for inducing BCR-ABL protein degradation through targeted ubiquitination. The compound has the advantages that the compound not only has excellent BCR-ABL protein degradation effect and anti-tumor activity, but also has small toxic and side effects on human bodies, and can be used for preparing anti-tumor drugs.

METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS

The present disclosure relates to compositions and methods for the treatment of diseases or disorders (e.g., cancer) with bi-steric inhibitors of mTOR in combination with RAS inhibitors. Specifically, in some embodiments this disclosure includes compositions and methods for inducing apoptosis of tumor cells and/or for delaying, preventing, or treating acquired resistance to RAS inhibitors using bi-steric mTOR inhibitors.

MDM2-HDAC double-target inhibitor, medicinal composition and preparation and application of MDM2-HDAC double-target inhibitor

The invention provides a MDM2-HDAC double-target inhibitor, a medicinal composition and preparation and application of the MDM2-HDAC double-target inhibitor. The MDM2-HDAC double-target inhibitor hasa structure as shown in formula I. The inhibitor with th